Former Dendreon CEO and Biotech Investment Analyst Form New Biotech Fund

By March 17, 2015 Alpine Bioventures News

Mitch Gold made a lot of money as the CEO of Dendreon (NASDAQ: DNDN), the Seattle-based cancer drug developer. David Miller made his reputation as an investment analyst with in-depth, bullish reports on the company.

Read the full article

Leave a Reply